INTRODUCTION {#s1}
============

Breast cancer is one of the most prevalent cancers, causing approximately half a million deaths per year worldwide \[[@R1]\]. Among women with breast cancer in Western countries, 30%--40% had advanced breast cancer (ABC) \[[@R2]\], in whom the median survival is 2--3 years, and the 5-year survival is 5--10% \[[@R3]\]. The principal goal of current therapies for the treatment of ABC patients is to seek a longer progression-free survival (PFS) and better symptom relief without increasing toxicity or compromising the quality of life (QoL) \[[@R4]\].

Among the chemotherapeutic agents currently available for the treatment of ABC, anthracyclines and taxanes are considered the most active and represent widely used treatment options \[[@R5], [@R6]\]. However, ABC is likely to progress due to primary or acquired resistance to these chemotherapy drugs. In addition, chemotherapy regimens containing anthracyclines and/or taxanes are now often considered as the standard option for adjuvant treatment of early breast cancer, especially in high-risk women, thus limiting their use in patients who subsequently develop disease relapse \[[@R7], [@R8]\].

New cytotoxic treatments for disseminated disease, such as gemcitabine, capecitabine, and vinorelbine, are now available for patients who have been previously treated with anthracyclines and taxanes \[[@R9]--[@R11]\]. Gemcitabine (Gemzar; 2′, 2′-difluorodeoxycytidine) is a pyrimidine antimetabolite and a specific analogue of deoxycytidine widely used in many kinds of solid tumors or neoplastic hematologic disorders. In ABC patients, the clinical outcomes of trials evaluating combination regimens containing gemcitabine are inconsistent. Many clinical trials with large sample size discovered that combination regimens containing gemcitabine could prolong both overall survival (OS) and PFS without increasing the occurrence of serious adverse events (ADEs) \[[@R12], [@R13]\]. Other medical centers argued that OS and PFS were similar between patients with or without gemcitabine regimens, and that gemcitabine was also associated with serious ADEs in individual cases \[[@R14]\]. The above results show that there are controversies about the benefit of gemcitabine-based combination regimens. In addition, some studies used gemcitabine as the first-line treatment \[[@R15]\], while studies used it as the second-line treatment in ABC patients who were pretreated with anthracycline- or taxane \[[@R16]\]. What\'s more, chemotherapy regimens for ABC patients are multifarious in different studies. In some studies, the chemotherapy regimen was used as a control group, and gemcitabine plus the same chemotherapy regimen as the experimental group \[[@R12], [@R17], [@R18]\]. In other studies, researchers used gemcitabine combination regimens as the experimental group, and another totally different chemotherapy regimen as the control group \[[@R19]\].

Given the above confusion, it is necessary to find out the significance of gemcitabine in ABC patients and testify whether gemcitabine-based combination regimens will bring more benefits to these patients. In the current study, we focused on gemcitabine-based chemotherapies versus non-gemcitabine-based therapies for the treatment of ABC.

RESULTS {#s2}
=======

Search strategy and selection criteria {#s2_1}
--------------------------------------

Initial searching of literature databases and trial registries revealed 479 published clinical trials and 66 registered ones (Figure [1](#F1){ref-type="fig"}). After removing 7 duplicates, 538 potentially eligible trials were left, of which 517 trials were excluded after reviewing the abstracts because the study design or outcome data did not satisfy the inclusion criteria. After reading the full text of the remaining 21 trials, 6 studies \[[@R20]--[@R25]\] were further excluded. The study of Feher *et al.* \[[@R20]\] was excluded because they used gemcitabine monotherapy in the experimental group, knowing that we only included studies with combination regimens containing gemcitabine. In addition, they enrolled postmenopausal women (aged 60 or older), which may produce selection bias for our analysis. The study of Park *et al.* \[[@R22]\] was also excluded because their patients were randomized to receive a combination of gemcitabine and vinorelbine or gemcitabine until disease progression followed by vinorelbine monotherapy. In Tomova *et al.*\'s study \[[@R25]\], the patients were randomized to receive gemcitabine plus docetaxel administered intravenously for a total of eight cycles or four cycles of docetaxel followed by four cycles of gemcitabine. In Seidman *et al.*\'s study \[[@R23]\], a crossover design was used. In above 3 studies \[[@R22], [@R23], [@R25]\], gemcitabine was used in both experimental and control groups, which was not eligible for our analysis. In Moinpour *et al.*\'s study \[[@R21]\], survival data were not available. In another study published in 2014 by Seidman *et al.* \[[@R24]\], a pooled result was from Chan *et al*.\'s study \[[@R26]\] and Seidman *et al.*\'s study \[[@R23]\]. For these reasons, we excluded above six studies and enrolled the rest 15 studies \[[@R12]--[@R18], [@R26]--[@R33]\] in our systematic review (The Selection flow was is shown in Figure [1](#F1){ref-type="fig"}).

![A flow diagram of the search strategy](oncotarget-09-7148-g001){#F1}

Altogether 15 studies \[[@R12]--[@R18], [@R26]--[@R33]\] with 8195 ABC patients were finally enrolled in our analysis (Table [1](#T1){ref-type="table"}). Of them, 12 studies \[[@R12]--[@R18], [@R26], [@R29]--[@R31], [@R33]\] had 2-arm design, and the remaining 3 studies \[[@R27], [@R28], [@R32]\] had 3 arms design. In addition, five studies \[[@R16], [@R26], [@R29]--[@R31]\] used gemcitabine as second-line chemotherapy, and the others used gemcitabine as first-line chemotherapy. Nevertheless, seven studies \[[@R12], [@R13], [@R15], [@R17], [@R18], [@R29], [@R31]\] used additional gemcitabine chemotherapy. With respect to different chemotherapy regimens in different studies, the gemcitabine combined taxanes chemotherapy regimen was most commonly used in nine studies \[[@R12], [@R13], [@R15], [@R17], [@R18], [@R26], [@R31]--[@R33]\] of the 15 included studies.

###### Baseline characteristics of included studies

  Study                         Arm                 Patients, *n*                                                                                                                                           Regimens
  ----------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Albain *et al.* 2008          Gem/Pac             266                                                                                                                                                     Gem 1250 mg/m[^2^]{.ul} i.v. d~1,8~, Pac 175 mg/m[^2^]{.ul} i.v. d~1~, q21d
  Pac                           263                 Pac 175 mg/m[^2^]{.ul} i.v. d~1~, q21d                                                                                                                  
  Amadori *et al.* 2013         Gem/Nvb             61                                                                                                                                                      Gem 1200 mg/m[^2^]{.ul} i.v. d~1,8~, Nvb 30 mg/m[^2^]{.ul} i.v. d~1,8~, q21d
  Pem/Cbp                       64                  Pem 600 mg/m[^2^]{.ul} i.v. d~1~, Cbp an AUC of 5 i.v. d~1~, q21d                                                                                       
  Brufsky *et al.* 2011         Gem/Pac/Beva        93                                                                                                                                                      Pac 90 mg/m[^2^]{.ul} i.v. d~1,8,15~, Beva 10 mg/kg i.v. d~1,15~, Gem 1500mg, d~1,15~,q28d
  Pac/Beva                      94                  Pac 90 mg/m[^2^]{.ul} i.v. d~1,8,15~, Beva 10 mg/kg i.v. d~1,15~, q28d                                                                                  
  Chan *et al.* 2009            Gem/Doc             152                                                                                                                                                     Gem 1000 mg/m[^2^]{.ul} i.v. d~1,8~, Doc 75 mg/m[^2^]{.ul} i.v. d~1~, q21d
  Cap/Doc                       150                 Cap 1250 mg/m[^2^]{.ul} bid d~1-14~, Doc 75 mg/m[^2^]{.ul} i.v. d~1~, q21d                                                                              
  Fountzilas *et al.* 2009      Pac/Cbp             136                                                                                                                                                     Pac 175 mg/m[^2^]{.ul} i.v. d~1~, Cbp an AUC of 6 d~1~, q3w for 6 cycles
  Gem/Doc                       134                 Gem 1000 mg/m[^2^]{.ul} i.v. d~1,8~, Doc 75 mg/m[^2^]{.ul} i.v. d~8~, q3w for 6 cycles                                                                  
  Pac                           136                 Pac 80 mg/m[^2^]{.ul} i.v., q1w for 12 cycles                                                                                                           
  Gómez *et al.* 2016           Lap/Cap             51                                                                                                                                                      Lap 1250 mg p.o. d~1-14~, Cap 2000 mg/m[^2^]{.ul} p.o. d~1-14~
  Lap/ Nvb                      45                  Lap 1250 mg p.o. d~1-14~, Nvb 25 mg/m[^2^]{.ul} i.v. d~1,\ 8~                                                                                           
  Lap/Gem                       46                  Lap 1250 mg p.o. d~1-14~, Gem 1000 mg/m[^2^]{.ul} d~1,\ 8~                                                                                              
  Joensuu *et al.* 2010         Doc                 115                                                                                                                                                     Doc 100 mg/m[^2^]{.ul} i.v.d~1~, q21d
  Doc/Gem                       122                 Doc 100 mg/m[^2^]{.ul} i.v.d~1~, q21d, Gem 1000 mg/m[^2^]{.ul} i.v. d~1,8,~q21d                                                                         
  Martín *et al.* 2007          Gem/Nvb             125                                                                                                                                                     Nvb 30 mg/m[^2^]{.ul} i.v. d~1,8,~ Gem 1200 mg/m[^2^]{.ul} i.v. d~1,8~, q21d
  Nvb                           126                 Nvb 30 mg/m[^2^]{.ul} i.v. d~1,8~, q21d                                                                                                                 
  Nielsen *et al.* 2011         Gem/Doc             170                                                                                                                                                     Gem 1200 mg/m[^2^]{.ul} i.v. d~1,8~, Doc 75 mg/m[^2^]{.ul} i.v. d~8,~ q21d
  Doc                           167                 Doc 100 mg/m[^2^]{.ul} i.v. d~1~, q21d                                                                                                                  
  Pallis *et al.* 2011          Gem/Nvb             74                                                                                                                                                      Nvb 25 mg/m[^2^]{.ul} i.v. d~1,15~, Gem 1000 mg/m[^2^]{.ul} i.v. d~1,15~ ,q28d for 6 cycles
  Cap                           74                  Cap 1250 mg/m[^2^]{.ul} bid, d~1-14~, q21d for 6 cycles                                                                                                 
  Papadimitriou *et al.* 2009   Doc/Gem             41                                                                                                                                                      Doc 35 mg/m[^2^]{.ul} i.v. d~1,8,15~, Gem 600 mg/m[^2^]{.ul} i.v. d~1,8,15~, q3w for 6 cycles
  Doc                           34                  Doc 40 mg/m[^2^]{.ul} i.v. d~1,8,15~, q3w for 6 cycles                                                                                                  
  Park *et al.* 2013            Gem/Pac → Gem/Pac   116                                                                                                                                                     Gem 1250 mg/m[^2^]{.ul} i.v. d~1,8~, Pac 175 mg/m[^2^]{.ul} i.v. d~1~, q21d
  Gem/Pac → Obersavation        115                 /                                                                                                                                                       
  Swain *et al.* 2013           Doc/Dox/Cyc         1630                                                                                                                                                    Dox 50 mg/m[^2^]{.ul} i.v., Cyc 500 mg/m[^2^]{.ul} i.v., Doc 75 mg/m[^2^]{.ul} i.v. q3w
  Dox/Cyc → Pac                 1634                Dox 60 mg/m[^2^]{.ul} i.v., Cyc 600 mg/m[^2^]{.ul} i.v., q2w for 4 cycles → Pac 175 mg/m[^2^]{.ul} i.v. q2w for 4 cycles                                
  Dox/Cyc → Gem/Pac             1630                Dox 60 mg/m[^2^]{.ul} i.v., Cyc 600 mg/m[^2^]{.ul} i.v., q2w for 4 cycles → Pac 175 mg/m[^2^]{.ul} i.v., Gem 2000 mg/m[^2^]{.ul} i.v.q2w for 4 cycles   
  Vici *et al.* 2011            Gem/Doc             36                                                                                                                                                      Gem 1000 mg/m[^2^]{.ul} i.v. d~1,8~, Doc 75 mg/m[^2^]{.ul} i.v. d~1~, q21d for 8 cycles
  Cap/Doc                       36                  Cap 1250 mg/m[^2^]{.ul} bid d~1-14~, Doc 75 mg/m[^2^]{.ul} i.v. d~1~, q21d for 8 cycles                                                                 
  Zielinski *et al.* 2005       Gem/Epi/Pac         124                                                                                                                                                     Gem 1000 mg/m[^2^]{.ul} i.v. d~1,4~,Epi 90 mg/m[^2^]{.ul} i.v. d~1~, Pac 175 mg/m[^2^]{.ul} i.v. d~1~, q21d
  5-FU/Epi/Ctx                  135                 5-FU 500 mg/m[^2^]{.ul} i.v. d~1~, Epi 90 mg/m[^2^]{.ul} i.v. d~1~,Ctx 500 mg/m[^2^]{.ul} d~1~, q21d                                                    

*Abbreviation*: Beva = bevacizumab, Cap = capecitabine, Cbp = carboplatin, Cyc = cyclophosphamide, Doc = docetaxel, Dox = doxorubicin, Epi = epirubicin, Gem = gemcitabine, Lap = lapatinib, Nvb = vinorelbine, Pac = paclitaxel, Pem = pemetrexed, 5-Fu = 5-fluorouracil.

Survival and tumor response {#s2_2}
---------------------------

In the three studies with 3-arm design \[[@R27], [@R28], [@R32]\], survival data were presented as survival curves, and therefore we only included studies with 2-arm design for survival analysis. But as these three studies provided objective response rate (ORR) data, they were eligible and included for ORR analysis.

Overall survival {#s2_3}
----------------

We first conducted meta-analysis about OS and found that nine studies \[[@R12]--[@R18], [@R26], [@R29]--[@R31], [@R33]\] with two-arm design evaluated OS. Pooled results showed that combination regimens containing gemcitabine significantly prolonged the OS of ABC patients \[hazard ratio (HR) = 1.14, 95% confidence interval (CI) 1.04 to 1.24)\] (Figure [2A](#F2){ref-type="fig"}).

![Comparisons of primary outcomes between gemcitabine-containing and non--gemcitabine-containing regimens\
(**A**) Overall survival, (**B**) Progression free survival, (**C**) Objective tumor response rate.](oncotarget-09-7148-g002){#F2}

Moreover, the OS data were also reported in studies with 3-arm design. In Fountzilas *et al.*\'s study \[[@R27]\], the median survival was 29.9 months in patients using paclitaxel and carboplatin, 26.9 months in patients using docetaxel and gemcitabine, and 41.0 months in patients using monotherapy of paclitaxel (*P* = 0.037). Nevertheless, Swain *et al.* \[[@R32]\] also presented the OS data. They randomized patients to receive six cycles of docetaxel (T), doxorubicin (A), and cyclophosphamide (C) (TAC), four cycles of dose-dense (DD) doxorubicin and cyclophosphamide followed by four cycles of DD paclitaxel (P) (AC→P), or DD AC→P with four cycles of gemcitabine (G) added to the DD paclitaxel (DD AC→PG)and found that OS was similar between patients with AC→PG and patients with AC→P (HR = 0.85, *P* = 0.130) or between patients with AC→PG and patients with TAC (HR = 0.86, *P* = 0.170). They showed that combination regimens containing gemcitabine did not bring significant benefits to ABC patients in terms of OS.

Progression free survival {#s2_4}
-------------------------

Pooled results from 12 studies with two-arm design \[[@R12]--[@R18], [@R26], [@R29]--[@R31], [@R33]\] revealed that patients received combination regimens containing gemcitabine had a significant better PFS (HR = 1.12, 95% CI 1.05 to 1.19) (Figure [2B](#F2){ref-type="fig"}).

In studies with 3-arm design, Fountzilas *et al.* \[[@R27]\] found that PFS was similar between their 3 groups (mean PFS: 11.5 months for paclitaxel and carboplatin; 10.4 months for docetaxel and gemcitabine; 11.4 months for paclitaxel; *P* = 0.570). Similarly, Gómez *et al.* \[[@R28]\] found that there was no significant difference in PFS between patients in three arms (mean PFS: 9.1 months for lapatinib and capecitabine; 7.0 months for lapatinib and vinorelbine; 6.8 months for lapatinib and gemcitabine; *P* = 0.476). Swain *et al.* \[[@R32]\] also showed a similar PFS between patients in three arms (AC→PG *vs.* TAC, HR = 0.93, *P* = 0.390; AC→PG *vs.* AC→P, HR = 1.07, *P* = 0.410).

Objective response rate {#s2_5}
-----------------------

Altogether 11 studies including 10 studies with two-arm design \[[@R12]--[@R18], [@R26], [@R29], [@R30], [@R33]\] and 1 study with three-arm design \[[@R28]\] presented the outcome of ORR and found that patients receiving combination regimens containing gemcitabine had a significant better ORR (risk ratio (RR) =1.16, 95% CI 1.03 to 1.30) (Figure [2C](#F2){ref-type="fig"}).

Toxicity {#s2_6}
--------

We carefully reviewed all the included studies in our analysis, and found that these studies included over 50 different ADEs. Among them, we provided nine most common ADEs and compared the incidence of grade 3 or 4 ADEs between patients receiving chemotherapy regimens with or without gemcitabine.

It was found that patients receiving combination regimens containing gemcitabine were more likely to have a higher incidence of neutropenia (RR = 1.33, 95% CI 1.25 to 1.42) (Figure [3A](#F3){ref-type="fig"}), thrombocytopenia (RR = 6.54, 95% CI 4.10 to 10.45) (Figure [3B](#F3){ref-type="fig"}), anemia (RR = 2.37, 95% CI 1.59 to 3.52) (Figure [3C](#F3){ref-type="fig"}), and an increased level of serum alanine aminotransferase (ALT) (RR = 2.22, 95% CI 1.34 to 3.69) (Figure [3D](#F3){ref-type="fig"}). In addition, patients receiving combination regimens containing gemcitabine were more likely to have less severe diarrhea (RR = 0.64, 95% CI 0.49 to 0.83) (Figure [3F](#F3){ref-type="fig"}), alopecia (RR = 0.86, 95% CI 0.74 to 0.99) (Figure [3H](#F3){ref-type="fig"}). The incidence of nausea/vomiting (RR = 0.87, 95% CI 0.68 to 1.11) (Figure [3E](#F3){ref-type="fig"}), fatigue (RR = 1.15, 95% CI 0.99 to 1.34) (Figure [3G](#F3){ref-type="fig"}), and neuropathy (RR = 1.22, 95% CI 0.99 to 1.50) was similar between 2 groups (Figure [3I](#F3){ref-type="fig"}).

![Comparisons of toxicity between gemcitabine-containing and non--gemcitabine-containing regimens\
(**A**) Neutropenia, (**B**) Thrombocytopenia, (**C**) Anemia, (**D**) Aalanine aminotransferase, (**E**) Nausea/vomiting, (**F**) Diarrhea, (**G**) Fatigue, (**H**) Alopecia, (**I**) Neuropathy.](oncotarget-09-7148-g003){#F3}

Quality of life {#s2_7}
---------------

Altogether 3 studies \[[@R16], [@R17], [@R27]\] reported the outcome of QoL in ABC patients. Amadori *et al.* \[[@R16]\] and Fountzilas *et al.* \[[@R27]\], reported that there was no significant difference in QoL between the treatment groups, while Brufsky *et al.* \[[@R17]\] found that QoL in patients with non-gemcitabine chemotherapy was better improved than that in patients with gemcitabine chemotherapy. According to our initial literature research, Moinpour *et al.* \[[@R21]\] found that QoL comparison study favored the gemcitabine combination therapy.

Subgroup analysis {#s2_8}
-----------------

Comparision between gemcitabine-containing and non--gemcitabine-containing regimens in first-line setting {#s2_9}
---------------------------------------------------------------------------------------------------------

Altogether 10 studies used gemcitabine as the first-line treatment \[[@R12]--[@R15], [@R17], [@R18], [@R27], [@R28], [@R32], [@R33]\] and the other 5 studies \[[@R19], [@R26], [@R29]--[@R31]\] used gemcitabine as the second-line chemotherapy. In studies using gemcitabine as first-line treatment, patients with gemcitabine-containing regimens had a significantly longer OS (HR = 1.19, 95% CI 1.07 to 1.32) (Figure [4A](#F4){ref-type="fig"}), PFS (HR = 1.17, 95% CI 1.08 to 1.27) (Figure [4C](#F4){ref-type="fig"}) and a higher ORR (RR = 1.16, 95% CI 1.02 to 1.32) (Figure [4E](#F4){ref-type="fig"}) than patients with non-gemcitabine-containing regimens. However, the trend is not seen in studies using gemcitabine as post first-line treatment (OS: HR = 0.98, 95% CI 0.81 to 1.18, Figure [4B](#F4){ref-type="fig"}; PFS: HR = 1.04, 95% CI 0.94 to 1.16, Figure [4D](#F4){ref-type="fig"}; ORR: RR = 1.15, 95% CI 0.92 to 1.45, Figure [4F](#F4){ref-type="fig"}).

![Comparisons of primary outcomes between studies using gemcitabine-containing regimens as first-line and second-line treatment\
(**A**) Overall survival (first-line), (**B**) Overall survival (second-line) (**C**) Progression free survival (first-line), (**D**) Progression free survival (second-line), (**E**) Objective tumor response rate (first-line), (**F**) Objective tumor response rate (second-line).](oncotarget-09-7148-g004){#F4}

Comparison of the efficacy between additional gemcitabine and gemcitabine replacement regimens {#s2_10}
----------------------------------------------------------------------------------------------

Of the 15 studies in our analysis, 7 studies used additional gemcitabine chemotherapy \[[@R12], [@R15], [@R17], [@R18], [@R29]--[@R31]\], and the other 8 used gemcitabine replacement regimens. In studies using additional gemcitabine chemotherapy, a significantly longer OS (HR = 1.17, 95% CI 1.06 to 1.30) (Figure [5A](#F5){ref-type="fig"}), PFS (HR = 1.20, 95% CI 1.11 to 1.30) (Figure [5C](#F5){ref-type="fig"}) and a higher ORR (RR = 1.23, 95% CI 1.06 to 1.42) (Figure [5E](#F5){ref-type="fig"}) were found, while the difference in OS (HR = 1.12, 95% CI 0.97 to 1.28) (Figure [5B](#F5){ref-type="fig"}), PFS (HR = 1.01, 95% CI 0.91 to 1.12) (Figure [5D](#F5){ref-type="fig"}) and ORR (RR = 1.06, 95% CI 0.89 to 1.27) (Figure [5F](#F5){ref-type="fig"}) was similar in patients receiving gemcitabine replacement regimens.

![Comparisons of primary outcomes between studies using additional gemcitabine and studies using gemcitabine as replacement chemotherapy\
(**A**) Overall survival (additional gemcitabine chemotherapy), (**B**) Overall survival (gemcitabine replacement chemotherapy) (**C**) Progression free survival (additional gemcitabine chemotherapy), (**D**) Progression free survival (gemcitabine replacement chemotherapy), (**E**) Objective tumor response rate (additional gemcitabine chemotherapy), (**F**) Objective tumor response rate (gemcitabine replacement chemotherapy).](oncotarget-09-7148-g005){#F5}

Efficacy of gemcitabine and taxanes combination therapy {#s2_11}
-------------------------------------------------------

Nine \[[@R12], [@R13], [@R15], [@R17], [@R18], [@R26], [@R31]--[@R33]\] of the 15 included studies used gemcitabine combined taxanes chemotherapy regimen. Pooled results of studies combining gemcitabine and taxanes showed that patients using the gemcitabine-containing regimens had a better OS (HR = 1.17, 95% CI 1.06 to 1.28) (Figure [6A](#F6){ref-type="fig"}), PFS (HR = 1.12, 95% CI 1.04 to 1.20) (Figure [6C](#F6){ref-type="fig"}) and ORR (RR = 1.17, 95% CI 1.01 to 1.35) (Figure [6E](#F6){ref-type="fig"}) than patients with non-gemcitabine-containing regimens. However, there was no significant difference in OS (HR = 0.78, 95% CI 0.60 to 1.26) (Figure [6B](#F6){ref-type="fig"}), PFS (HR = 1.12, 95% CI 0.99 to 1.26) (Figure [6D](#F6){ref-type="fig"}) and ORR (RR = 1.14, 95% CI 0.94 to 1.36) (Figure [6F](#F6){ref-type="fig"}) between studies using non-gemcitabine-taxanes-combination therapy.

![Comparisons of primary outcomes between studies with gemcitabine- taxanes-based regimens and studies with non-gemcitabine-taxanes-based regimens\
(**A**) Overall survival (gemcitabine-taxanes-based regimens), (**B**) Overall survival (non-gemcitabine-taxanes-based regimens) (**C**) Progression free survival (gemcitabine-taxanes-based regimens), (**D**) Progression free survival (non-gemcitabine-taxanes-based regimens), (**E**) Objective tumor response rate (gemcitabine-taxanes-based regimens), (**F**) Objective tumor response rate (non-gemcitabine-taxanes-based regimens).](oncotarget-09-7148-g006){#F6}

During the initial literature searching process, we found that there was a meta-analysis comparing the safety and efficacy of gemcitabine and taxanes combination therapy in ABC patients \[[@R34]\]. They found that ORR and time to progression were superior for gemcitabine/taxanes-treated patients (ORR, odd ratio = 1.28, 95% CI 1.07 to 1.53; time to progression, HR = 0.80, 95% CI 0.71 to 0.89). And gemcitabine/ taxanes-based combination significantly improved OS in the first-line subgroup (HR = 0.84; 95% CI 0.71 to 0.99).

Sensitivity analysis {#s2_12}
--------------------

To test whether our meta-analysis results were skewed because of the study with high risk of bias, we repeated the analyses after excluding the study \[[@R14]\] (the initial quality assessment of included studies is shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The results for PFS (HR = 1.12, 95% CI 1.05 to 1.20) ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) and ORR (RR = 1.15, 95% CI 1.02 to 1.30) ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) were similar to those obtained when including the study with high risk of bias, suggesting that our meta-analysis is reliable.

Moreover, we also switched the fix- and random-model to test the sensitivity of the outcome, and found that recalculated ORR (RR = 1.14, 95% CI 1.00 to 1.30, random model) ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}) was similar to the previous ORR (RR = 1.16, 95% CI 1.03 to 1.30, fix model).

Publication bias {#s2_13}
----------------

Funnel plots were generated and analyzed using Egger\'s tests in order to assess the risk of publication bias in all included studies. The funnel plots for ORR appeared to be symmetrical, suggesting the absence of bias. This was corroborated by Egger\'s test (*t* = −0.77, *P* = 0.459) ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

The treatment of ABC is a clinical challenge because of its propensity for late presentation with inoperable disease, aggressive tumor biology, and resistance to chemotherapy \[[@R35]--[@R37]\]. Taxane/anthracycline-based chemotherapy is the treatment of choice in most cancer centers and countries for the treatment of ABC, and a wide variety of single agents or combination therapies have been investigate for patients previously treated with both a taxane and an anthracycline \[[@R38]\]. As an outstanding anti-tumor agent, gemcitabine has been evaluated in many randomized controlled trials for ABC, showing a favorable clinical outcome \[[@R25], [@R29]\]. However, whether gemcitabine-containing chemotherapy is better than non--gemcitabine-containing treatment still lacks adequate evidence. To compare the efficacy and tolerability of gemcitabine-containing chemotherapy in the treatment of ABC patients with sufficient statistical power, we performed this systematic review to overcome the statistical limitations (for instance, low case load) of the individual trials by comparing the treatment efficacy, safety profile and survival benefit between various subgroups.

This systematic review revealed that gemcitabine-containing chemotherapy was associated with significantly enhanced OS (HR = 1.14, 95% CI 1.04 to 1.24), PFS (HR = 1.12, 95% CI 1.05 to 1.19), and ORR (RR = 1.16, 95% CI 1.03 to 1.30) over non--gemcitabine-containing chemotherapy. Our initial review revealed another meta-analysis that also conducted a similar comparison \[[@R39]\]. Interestingly, they reported that OS, PFS and ORR were similar between ABC patients with or without gemcitabine-containing regimens. In their study, 9 trials including 2651 patients \[[@R12], [@R14], [@R15], [@R17], [@R18], [@R20], [@R26], [@R29], [@R30]\] were eligible for the meta-analysis. Compared with their inclusion, we additionally include 7 studies, and excluded Feher *et al.*\'s study \[[@R20]\] because they used monotherapy of gemcitabine in the experimental group and only included postmenopausal women aged 60 years or older, which we were afraid may produce significant selection bias in our analysis. According to Brufsky *et al.*\'s study \[[@R17]\], gemcitabine-containing chemotherapy was associated with significantly improved ORR as compared with non-gemcitabine-containing chemotherapy in patients younger than 65 years. Nevertheless, the trend was not significant in patients older than 65 years, indicating that age may affect the survival outcome. Included patients with older age were often postmenopausal women, and estrogen deficiency may affect the efficacy of chemotherapy \[[@R40]\]. Li *et al.* \[[@R39]\] found a significant bias in Feher *et al.*\'s study and therefore excluded it from their meta-analysis. Interestingly, they also found that the insignificant difference between 2 arms turned significant. The dramatic change demonstrated a selection bias and inconvincible results in Li *et al.*\'s \[[@R39]\] study, and we excluded Feher *et al.*\'s study and conducted a new systematic review in order to provide more authentic results.

Severe toxicity is an important concern when combination chemotherapy is considered, especially in elderly patients and those who have poor PS score. Thus, toxicity and QoL have become equally important in assessing the therapeutic efficacy and determining the course of palliative chemotherapy. Toxicity is a major concern with gemcitabine. It was found in our study that additional use of gemcitabine increased the incidence of grade 3--4 hematopoietic system toxicity including neutropenia, thrombocytopenia and anemia, and increased the serum level of ALT \[[@R41]\]. Although gemcitabine combining regimens significantly increased the incidence of grade 3--4 hematopoietic and liver function impairment, few serious AEDs were reported. According to Zielinski *et al.* \[[@R14]\] thrombocytopenia did not constitute a clinical problem in patients treated with gemcitabine-combining regimens, because no bleeding episodes was reported. The rate of grade 3 and 4 myelosuppressive activity in patients with second-line therapy was lower as compared with first-line treatment studies with similar toxicity profiles, which could be attributed to the difference in the total durations of drug exposure in the previous treatment \[[@R42]\]. Furthermore, grade 3 or 4 hematologic toxicities were not commonly associated with clinical events such as transfusions \[[@R20]\]. Viewing the ADEs by age, some differences in toxicities would be noted. In patients with elder age, the severity and the incidence may increase \[[@R20]\]. Thus the toxic effects of the gemcitabine combination regimens are manageable when they are used with caution in elderly patients. QoL difference between patients with or without gemcitabine containing chemotherapy varies greatly, and further investigation is required before a convincing conclusion can be drawn.

Subgroup analysis of first- or second-line therapy revealed that gemcitabine containing chemotherapy was beneficial to ABC patients when it was used as the first-line therapy. Interestingly, gemcitabine has shown a modest activity as a single agent in ABC, especially when the drug was used as second-line or third-line treatment \[[@R43]\]. The satisfied survival benefit may be attributed to the included populations. Gemcitabine containing chemotherapy was used as the second-line therapy in these patients, mainly because of drug resistance to the previous first-line therapy or disease progression. Indeed, any therapy may not be as effective as expected in these patients. Thus, the result of survival benefits of gemcitabine containing regimens in first-line treatment would help clinical doctors make rational and efficacious chemotherapeutic protocols. According to Carrick *et al.* \[[@R44]\], combination regimens had a higher response rate than single-drug regimens, but sequential use of a single agent was associated with better QoL and similar or nearly similar survival, which may be the reason why mono-chemotherapy has widely been accepted as a better approach to breast cancer management. Nevertheless, the above-mentioned results were not based on gemcitabine containing regimens. Subgroup analysis in our study showed that gemcitabine, when used as an additional agent in chemo-regimens, brought significant survival and tumor response benefits as compared with gemcitabine replacement chemotherapy. In addition, a large multicenter trial reported that the combination was more effective than single-agent paclitaxel in terms of the response rate, time-to-disease progression, and OS \[[@R12]\] suggesting that gemcitabine combining regimens could bring better survival outcomes and tumor response. In our study, gemcitabine containing regimens increased the incidence of hematologic toxicity, though it was manageable.

In addition, QoL comparison in some studies favored the gemcitabine combination therapy. However, we did not compare the difference in survival and tumor response between the gemcitabine combination regimen and the single gemcitabine regimen. Further study is required to compare the efficacy of single gemcitabine in ABC patients. It was found in our study that gemcitabine combined with taxanes was the most commonly used regimen. Currently, taxanes are usually introduced early in the treatment of ABC patients' treatment. In addition, taxanes are commonly used in patients with no or minimal prior anthracycline exposure and/or in combination with anthracyclines and gemcitabin \[[@R45]\]. Gemcitabine combined with taxanes doublet is a well-tolerated choice for ABC women after adjuvant anthracycline therapy or in whom the cardiotoxic effects of anthracyclines preclude its use \[[@R12]\]. Despite the manageable toxicity, the analysis of the global QoL end point from the QoL companion study still favored the regimens containing gemcitabine and taxanes \[[@R21]\]. A recently published meta-analysis compared the efficacy and toxicity in patients receiving chemotherapy with or without gemcitabine-taxanes-based regimens \[[@R34]\], and found that ORR and time to progression were superior to gemcitabine and taxanes treated patients, which is consistent with our subgroup analysis. They also found that gemcitabine-taxanes-based combination also significantly improved OS in the first-line subgroup (HR = 0.84; 95% CI 0.71 to 0.99). All evidence suggests that gemcitabine-taxanes-based chemotherapy may be a feasible regimen for ABC patients.

The biggest limitation of this systematic review is the heterogeneity of the included studies. The study designs and study inclusion criteria are totally different between different studies, and the pooled results might have biases. In order to make our results more convincible, we conducted sensitivity analysis. By excluding the study with high risk of bias, the final results for PFS and ORR are similar to previous results, suggesting that our meta-analyses are reliable. In addition, we also switched the fix- and random-model to test the sensitivity of the outcome, and found that recalculated ORR (RR = 1.14, 95% CI 1.00 to 1.30, random model) were similar to previous ORR (RR = 1.16, 95% CI 1.03 to 1.30, fix model). Additionally, funnel plots of publication bias for ORR appear to be symmetrical, suggesting the absence of bias. All above evidence shows that the results in our study are convincible.

In conclusion, a gemcitabine-based regimen possesses meaningful anti-tumor activity in the treatment of ABC, repeatedly demonstrating outcomes favored to non--gemcitabine-containing agents, especially for first-line treatment in ABC patients. Gemcitabine-based regimens could serve as promising regimens, although increased hematologic toxicity should be considered.

METHODS {#s4}
=======

This meta-analysis was conducted according to PRISMA guidelines (Checklist S1).

Literature search strategy {#s4_1}
--------------------------

Systematic searches of the following electronic databases were conducted through January 2017 without language restrictions: MEDLINE, EMBASE, the Cochrane Library, and the Chinese National Knowledge Infrastructure. We also searched five primary clinical trial registries recognized by the WHO International Clinical Trial Registry Platform: Australia and New Zealand Clinical Trial Registry ([www.anzctr.org.au/](http://www.anzctr.org.au/)), Chinese Clinical Trial Register ([www.chictr.org.cn](http://www.chictr.org.cn)), ISRCTN ([www.controlled-trials.com/isrctn/](http://www.controlled-trials.com/isrctn/)), U.S. National Institutes of Health Clinical Trials Database ([www.clinicaltrials.gov/](http://www.clinicaltrials.gov/)), and Clinical Trials Registry-India ([www.ctri.in:8080/Clinicaltrials/index.jsp](http://www.ctri.in:8080/Clinicaltrials/index.jsp)) \[[@R46], [@R47]\]. Eligible studies were identified using any of the following index words: "gemcitabine," "chemotherapy," and "breast cancer". Relevant reviews and meta-analyses comparing combination regimens with or without gemcitabine for ABC were examined manually to identify additional eligible studies.

Inclusion criteria {#s4_2}
------------------

Studies included in our analysis had to satisfy the following criteria: (1) randomized clinical trials; (2) trials including a group that received combination regimens containing gemcitabine and a group that received chemotherapy regimens without gemcitabine; (3) trials reporting data on OS or PFS as the clinical outcome; (4) trials including ABC with histologically confirmed invasive breast cancer and measurable or non-measurable distant metastases as confirmed by histology and/or radiology); (5) trials reporting sufficient data to allow calculation of the RR or HR with 95% CI.

Types of outcome measures {#s4_3}
-------------------------

Primary outcomes evaluated in the meta-analysis were OS, PFS and tumor response. Tumor response was classified according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) \[[@R48], [@R49]\]. Tumor responses were classified as complete response, partial response, stable disease and progressive disease. The ORR was calculated by summing the complete response rate and partial response rate. Secondary outcomes were toxicity and QoL. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria (Version 3.0). We only included grade 3 or 4 common ADEs into our analysis.

Data extraction {#s4_4}
---------------

The following data were extracted independently by two reviewers (Z.B.X and Y.F.Z): the first author\'s name, year of publication, tumor characteristics, number of patients, and line of therapy. For each group, the intervention, number of patients, ORR, duration of response, OS, PFS and toxicity were also collected. Any disagreements about study eligibility or extracted data were arbitrated by a third reviewer (D.L.F).

Quality assessment {#s4_5}
------------------

Two reviewers (Z.B.X and Y.F.Z) independently evaluated all the included trials and independently assessed the risk of bias for each study using criteria specified by Cochrane Collaboration Back Review Group \[[@R50]\].

Statistical analysis {#s4_6}
--------------------

All statistical calculations were performed using Stata 12.0 (Stata Corp, College Station, TX, USA). Mantel-Haenszel RRs with corresponding 95% CIs were calculated for tumor response. Survival data (OS and PFS) were extracted from survival curves \[[@R51]\] and HRs with 95% CIs were calculated. The meta-analysis was carried out on an 'intention-to-treat' basis. Heterogeneity was assessed by calculating *I*^2^. When *I*^2^ was less than 50%, a fixed-effects model was used; when *I*^2^ was more than 50%, a random-effects model was used. Homogeneity between trials was assessed using the χ^2^ test with the significance threshold set at *P* \> 0.1. To evaluate the robustness of the meta-analysis results, we repeated all meta-analyses using the other type of model (fixed- or random-effects); if both models gave the same meta-analysis results, we judged the result to be reliable. Publication bias was assessed using Egger\'s test and funnel plots \[[@R52], [@R53]\] in Stata 12.0.
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ABC

:   advanced breast cancer

ADE

:   adverse event

CI

:   confidence interval

HR

:   hazard ratio

ORR

:   objective response rate

OS

:   overall survival

PFS

:   progression free survival

QoL

:   quality of life

RR

:   risk ratio
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